
New Drug Daraxonrasib Doubles Pancreatic Cancer Survival
A breakthrough oral drug called daraxonrasib has doubled survival times for patients with advanced pancreatic cancer. The historic achievement conquers a stubborn genetic mutation once considered undruggable for over four decades.








